Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759229 | 0.87 | TNNI3K (0.56) | EGFRPTGS2AURKAMEN1KMT2A | |
| SCHEMBL759096 | 0.86 | MKNK1 (0.51) | EGFRPTGS2AURKAMEN1KMT2A | |
| SCHEMBL759242 | 0.84 | AURKA (0.55) | AURKAAURKB | |
| SCHEMBL759860 | 0.83 | AURKA (0.52) | PTGS2AURKAMEN1KMT2ARXFP1 | |
| SCHEMBL735116 | 0.81 | PTGS2 (0.70) | EGFRPTGS2AURKAMEN1KMT2A | |
| SCHEMBL757854 | 0.80 | PTGS2 (0.69) | EGFRPTGS2AURKAMEN1KMT2A | |
| SCHEMBL759953 | 0.80 | PTGS2 (0.69) | EGFRPTGS2AURKAMEN1KMT2A | |
| SCHEMBL759858 | 0.77 | PTGS2 (0.56) | EGFRPTGS2AURKAAURKB | |
| SCHEMBL13399926 | 0.76 | EGFR (0.43) | EGFRAURKAAURKB | |
| SCHEMBL763940 | 0.76 | MAPK10 (0.39) | MEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134658-A2 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | EGFR 1351/4885PTGS2 4714/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.